IL17A and neoplasm: The role of the IL23/Th17 pathway in CAC pathogenesis is not completely clear, but IL-17A appears to drive tumor formation in mouse models for inflammation-induced cancer, as both a blockade of IL-17A by anti-IL-17A antibodies [135], and genetic deletion of IL-17A [136] was associated with decreased tumor size and number.